An interventional study of Early Catheter-Interventional Treatment and Conventional care in Pulmonary Embolism Acute Massive, sponsored by Leipzig Heart Science gGmbH. Recruiting at 18 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Leipzig Heart Science gGmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Pulmonary Embolism with a site in Germany — 6 open to participants now, 8 under way, 2 of them phase 3. Pulmonary Embolism · Germany.
Among the 55 studies in Pulmonary Embolism with a site in Germany, this one is the 22nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 with no phase, and was the 54th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →6 of the 55 studies in Pulmonary Embolism with a site in Germany are open now. Recruiting first, the newest first:
Inari Medical · Sites in Germany, France, Italy and 2 more countries
Ages 18+
Inari Medical · Sites in Germany, United States, France and 3 more countries
Ages 18+
Prof. Stavros Konstantinides, MD · Sites in Germany, Austria
Ages 18–85
Penumbra Inc. · Sites in Germany, United States, Australia and 9 more countries
Ages 18+
Johannes Gutenberg University Mainz · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 4
First in 2003; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 174 across 430 interventional studies indexed under Pulmonary Embolism.
Median enrollment 544 across the 33 interventional studies, 880 across the 21 observational. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 55 have an industry lead sponsor. The 10 most frequent:
Leipzig Heart Science gGmbH is the lead sponsor of 8 studies on the registry; 7 are open to participants now.
Leipzig Heart Science gGmbH has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
4 of the studies in Pulmonary Embolism with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
| NCT06672081Leipzig Heart Science gGmbHEarly Catheter-directed Treatment of High Risk Pulmonary Embolism | 2027-06-30 |
| NCT06588634Inari MedicalThe PERSEVERE Study | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Pulmonary Embolism with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multicenter, open label, randomized controlled clinical trial to compare the effects of an early catheter-directed treatment plus conventional care with conventional care in patients with high-risk pulmonary embolism
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pulmonary embolism as confirmed by CT angiogram with high mortality risk as defined by ESC guidelines:
a) One of the following: i. Cardiac arrest or ii. obstructive shock (systolic BP \<90 mmHg or vasopressors required to achieve a BP ≥90 mmHg despite an adequate filling status), in combination with end-organ hypoperfusion (cold, clammy skin, oliguria or serum lactate ≥2 mmol/L) and b) Signs of right-ventricular dysfunction on transthoracic echocardiogram or CT scan
Exclusion Criteria:
Contraindications to systemic fibrinolytic treatment or anticoagulation*
Pregnancy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the conventional care group will receive guideline directed therapy including reperfusion treatment. If no clinically relevant hemodynamic improvement occurs, catheter-interventional treatment may be used as stated in the current ESC-guidelines
Drug: Conventional care
Patients in this group will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration, if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these. Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation. The choice of the catheter types and sizes will be left to the treating interventionalists' discretion.
Procedure: Early Catheter-Interventional Treatment · Drug: Conventional care
Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.
reperfusion treatment
Composite endpoint of mortality (all-cause) and recurrent cardiac arrest or persistent / recurrent shock
1. mortality (all-cause) up to 7 days after randomization and 2. either one of the following 1. recurrent cardiac arrest or 2. persistent / recurrent shock (systolic BP \<90 mmHg or vasopressors or ECMO required to achieve a systolic BP ≥90 mmHg, in combination with end-organ hypoperfusion (cold, clammy skin, oliguria or serum lactate ≥2 mmol/L) 24 hours after randomization
Time frame: 7 days
All-cause mortality
All-cause mortality at day 7 after randomization
Time frame: 7 days
PE-related mortality
PE-related mortality at day 7 after randomization
Time frame: 7 days
Mortality (all-cause)
Mortality (all-cause) at day 30 after randomization
Time frame: 30 days
Bail out therapy
Bail out therapy at day 7 after randomization
Time frame: 7 days
GUSTO moderate or severe bleeding
GUSTO moderate or severe bleeding up to 7 days after randomization
Time frame: 7 days
VA-ECMO use
VA-ECMO use between randomization and day 7 after randomization
Time frame: 7 days
Change in echocardiographic parameters
Change in echocardiographic parameters (RV/LV ratio, RV-strain, TAPSE) 24h after randomization
Time frame: 24 hours
Days of ICU stay
Days of ICU stay
Time frame: 30 days
Time to hemodynamic stabilization
Time to hemodynamic stabilization
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.
Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 30 months is above that.
Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leipzig Heart Science gGmbH